U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07168291) titled 'Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma' on Sept. 05.
Brief Summary: This is an open-lable, single arm, non-randomized study to evaluate the primary safety and efficacy of the novel bispecific AbTCR (anti-CD19/CD22)-T cells in patients with relapsed or refractory B-cell lymphoma
Study Start Date: Dec. 31, 2025
Study Type: INTERVENTIONAL
Condition:
Diffuse Large B Cell Lymphoma (DLBCL)
Follicular Lymphoma ( FL)
Burkitt Lymphoma
Intervention:
DRUG: Conditioning chemotherapy followed by AbTCR (anti-CD19/CD22)-T cell infusion
Cyclophosphamide 250 mg/m2 and fludarabine 30 mg/m2 IV...